Mary Ann Gray
Known title: DirectorCIK: 0001261974
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Sarepta Shares New DM1 Data at Oligonucleotide Meeting. Sarepta Therapeutics presented new preclinical data for SRP-1003, a treatment for myotonic dystrophy type 1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. The data indicated robust knockdown of pathogenic DMPK RNA in the nucleus. This update highlights the company's ongoing research efforts, while the stock currently trades near its 52-week low with a volume spike.
Transaction History
| KROS | ▲ Buy | Grant | 7,142 | $0 | 6/3/2026 | View on chart |
| BCAB | ▲ Buy | Grant | 23,500 | $0 | 6/18/2025 | View on chart |
| KROS | ▲ Buy | Grant | 5,250 | $0 | 6/4/2025 | View on chart |
| BCAB | ▲ Buy | Grant | 16,500 | $0 | 6/13/2024 | View on chart |
| BCAB | ▲ Buy | Grant | 5,995 | $0 | 12/31/2023 | View on chart |
| BCAB | ▲ Buy | Grant | 8,676 | $0 | 9/30/2023 | View on chart |
| BCAB | ▲ Buy | Grant | 4,916 | $0 | 6/30/2023 | View on chart |
| BCAB | ▲ Buy | Grant | 5,503 | $0 | 3/31/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 2,953 | $0 | 3/7/2022 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 967 | $0 | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial
Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.
Keros Therapeutics Doses First Patient in Phase 2 Rinvatercept Trial. Keros Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating rinvatercept for Duchenne Muscular Dystrophy. This milestone marks a significant step in the development of the company's lead candidate. The stock is currently trading near its support level, with analysts setting an average price target of $19.83.